Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

CVM - CEL-SCI Corporation Последние новости | Finranks

Home

/

CVM

C

CEL-SCI Corporation (CVM)

ASE – Цена в реальном времени. Валюта: USD

1.19

-0.22 (-15.60%)

При закрытии: May 12, 2026, 4:00 PM EDT

1.12

-0.06 (-4.95%)

До открытия: May 13, 2026, 9:01 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

CEL-SCI Corporation Announces Pricing of Public Offering

CEL-SCI Corporation Announces Pricing of Public Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Announces Pricing of Public Offering.

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia.

CEL-SCI Reports Fiscal First Quarter 2026 Results

CEL-SCI Reports Fiscal First Quarter 2026 Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

CEL-SCI Reports Fiscal 2025 Results

CEL-SCI Reports Fiscal 2025 Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the LD Micro "Main Event" Investor Conference on October 21, 2025. You can register to watch the virtual presentation at 9:30 a.m.

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of $5.7 million offering priced at-the-market under NYSE American rules.

Видео

No Data

There is no data to display

Пресс-релизы

CEL-SCI Corporation Announces Pricing of Public Offering

CEL-SCI Corporation Announces Pricing of Public Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Announces Pricing of Public Offering.

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

11.05.2026

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia.

CEL-SCI Reports Fiscal First Quarter 2026 Results

CEL-SCI Reports Fiscal First Quarter 2026 Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

CEL-SCI Reports Fiscal 2025 Results

CEL-SCI Reports Fiscal 2025 Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.